Skip to content

Protea Biosciences Group, Inc.: 10-Q filed 2012-11-13

What Protea Biosciences Group, Inc. reported in its quarterly report filed 2012-11-13 (fiscal Q3 2012): 30 published measures, 100 facts as tagged in accession 0001144204-12-061111.

This filing

Form
10-Q (quarterly report)
Filed
2012-11-13
Fiscal period
fiscal Q3 2012
Accession
0001144204-12-061111 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Protea Biosciences Group, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-09-304,143,921USD
At 2011-12-314,649,073USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-09-30-7,544,640USD
At 2011-12-31-4,503,782USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-09-3056,345USD
At 2011-12-31505,277USD
At 2011-09-30656,988USD
At 2010-12-31410,696USD
At 2001-07-120USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-2,230,975USD92
2012-01-01 to 2012-09-30-7,758,104USD274
2001-07-13 to 2012-09-30-45,201,523USD4098
2011-07-01 to 2011-09-30-2,851,082USD92
2011-01-01 to 2011-09-30-8,483,845USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-09-30-6,688,148USD274
2001-07-13 to 2012-09-30-35,761,620USD4098
2011-01-01 to 2011-09-30-7,163,082USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-09-306,599,805USD274
2001-07-13 to 2012-09-3040,249,569USD4098
2011-01-01 to 2011-09-308,070,271USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-01-01 to 2012-09-30-340,645USD274
2001-07-13 to 2012-09-30-4,426,479USD4098
2011-01-01 to 2011-09-30-636,706USD273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2012-07-01 to 2012-09-3029,245,418shares92
2012-01-01 to 2012-09-3028,442,560shares274
2001-07-13 to 2012-09-3010,380,600shares4098
2011-07-01 to 2011-09-3022,676,938shares92
2011-01-01 to 2011-09-3022,666,938shares273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2012-07-01 to 2012-09-300USD92
2012-01-01 to 2012-09-300USD274
2001-07-13 to 2012-09-300USD4098
2011-07-01 to 2011-09-300USD92
2011-01-01 to 2011-09-300USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-09-303,008,219USD
At 2011-12-313,319,219USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-01-01 to 2012-09-30238,484USD274
2011-01-01 to 2011-09-30252,903USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-2,064,882USD92
2012-01-01 to 2012-09-30-7,359,523USD274
2001-07-13 to 2012-09-30-43,356,088USD4098
2011-07-01 to 2011-09-30-2,437,569USD92
2011-01-01 to 2011-09-30-7,832,369USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-09-301,111,409USD
At 2011-12-311,312,222USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2012-07-01 to 2012-09-30138,621USD92
2012-01-01 to 2012-09-30367,309USD274
2001-07-13 to 2012-09-301,855,919USD4098
2011-07-01 to 2011-09-30414,455USD92
2011-01-01 to 2011-09-30658,455USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-09-309,467,194USD
At 2011-12-316,963,401USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2012-09-3061,335USD
At 2011-12-3176,650USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2012-09-30830,319USD
At 2011-12-31223,336USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2012-07-01 to 2012-09-301,111,652USD92
2012-01-01 to 2012-09-303,825,172USD274
2001-07-13 to 2012-09-3024,478,532USD4098
2011-07-01 to 2011-09-301,457,330USD92
2011-01-01 to 2011-09-304,023,947USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-07-01 to 2012-09-301,118,768USD92
2012-01-01 to 2012-09-304,103,345USD274
2001-07-13 to 2012-09-3022,105,155USD4098
2011-07-01 to 2011-09-301,195,618USD92
2011-01-01 to 2011-09-304,349,896USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-09-3029,616,994shares
At 2011-12-3127,061,498shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2012-09-30-5,125USD
At 2011-12-3114,819USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2012-09-303,474,647USD
At 2011-12-312,587,837USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2012-09-3024,293USD
At 2011-12-3117,632USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-2,230,975USD92
2012-01-01 to 2012-09-30-7,758,104USD274
2001-07-13 to 2012-09-30-45,201,523USD4098
2011-07-01 to 2011-09-30-2,851,082USD92
2011-01-01 to 2011-09-30-8,483,845USD273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-2,228,839USD92
2012-01-01 to 2012-09-30-7,778,048USD274
2001-07-13 to 2012-09-30-45,206,648USD4098
2011-07-01 to 2011-09-30-2,838,732USD92
2011-01-01 to 2011-09-30-8,508,036USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2012-01-01 to 2012-09-30749,155USD274
2001-07-13 to 2012-09-304,138,509USD4098
2011-01-01 to 2011-09-30943,612USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-166,093USD92
2012-01-01 to 2012-09-30-398,581USD274
2001-07-13 to 2012-09-30-1,845,435USD4098
2011-07-01 to 2011-09-30-413,513USD92
2011-01-01 to 2011-09-30-651,476USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2012-01-01 to 2012-09-304,406,851USD274
2001-07-13 to 2012-09-3024,436,340USD4098
2011-01-01 to 2011-09-301,710,500USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-09-30-15,315USD274
2001-07-13 to 2012-09-3061,335USD4098
2011-01-01 to 2011-09-3041,530USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-09-30606,983USD274
2001-07-13 to 2012-09-30830,319USD4098
2011-01-01 to 2011-09-30-4,208USD273

Inspect the source

Entity
Protea Biosciences Group, Inc. / CIK 0001335103
Captured
SEC response SHA-256
6b487b6d6aa0a735e07855358b10c0014003743452cad5b8c8bf2155ac6c1078

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001335103.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))